Neutralization of stratum corneum to treat hyperkeratotic skin lesions
AssigneeThe Regents of the University of California
InventorsPeter M. Elias, Kenneth R. Feingold, Joachim W. Fluhr, Theodora M. Mauro, Martin J. Behne
Life of this patent
Estimating the term…
Abstract
Hyperkeratotic skin lesions are treated by the topical administration of inhibitors of hydrogen ion pumps, transporters, and antiporters, or buffers with a pH of 7.0 or greater, and inhibitors of physiological processes that generate free fatty acids from complex lipids.
Claims48
A method for treating the epidermis of a terrestrial mammalian subject suffering from hyperkeratosis, visible scale or both due to increased intercellular cohesion of the stratum corneum, said method comprising administering to said epidermis a topical composition comprising an active ingredient that neutralizes the pH of the stratum corneum and is a member selected from the group consisting of inhibitors of proton pumps, transporters or antiporters, inhibitors of free fatty acid generation from complex lipids, inhibitors of proteolytic processes that generate organic acids and buffers with a pH of 7.0 or greater, said active ingredient being present in a concentration that is effective in raising the pH of said epidermis thereby reducing intercellular cohesion and resulting in easier detachment of normal stratum corneum and easier removal of hyperkeratotic stratum corneum.
A method for manipulating the epidermis of a terrestrial mammalian subject with the purpose of providing improved transdermal delivery of co- or sequentially applied drugs or nutrients for systemic, regional or local applications, said method comprising administering to said epidermis a topical composition comprising an active ingredient that neutralizes the pH of the stratum corneum and is a member selected from the group consisting of inhibitors of proton pumps, transporters or antiporters, inhibitors of free fatty acid generation from complex lipids, inhibitors of proteolytic processes that generate organic acids, and buffers with a pH of 7.0 or greater, said active ingredient being present in a concentration that is effective at raising the pH of said epidermis with the purpose of reducing intercellular cohesion and integrity of the stratum corneum to breakdown the epidermal permeability barrier.
Dependencies are inferred from the claim text.